Obesity Clinical Trial
Official title:
Pathobiology and Reversibility of Prediabetes in a Biracial Cohort (PROP-ABC)
The reasons for the epidemics of diabetes and prediabetes, and why individuals from certain populations suffer at higher rates are not well known. In the Pathobiology and Reversibility of Prediabetes in a Biracial Cohort (PROP-ABC) study, nearly 400 African Americans and Caucasians whose parents have type 2 diabetes will undergo repeated testing to determine what factors lead to the occurrence of prediabetes, and whether race still plays a major role in a setting where everyone being studied has one or both parents with diabetes. The PROP-ABC Study also will test the hypothesis that the ability of intensive lifestyle intervention to reverse prediabetes and return people's metabolism back to normal is dependent on how long people have had prediabetes.
The Pathobiology and Reversibility of Prediabetes in a Biracial Cohort (PROP-ABC) study is
following an extant cohort of 376 initially normoglycemic African American and Caucasian
offspring of parents with type 2 diabetes for an additional 5years. The subjects were
enrolled between 2006 and 2009 and have been followed up to 2012, during which 10 have
developed diabetes and 101 developed prediabetes, without evidence of racial disparities.
The objectives of PROP-ABC are to gain a fuller understanding of the natural history and
predictors of early glucose abnormalities, determine the role of race during the second wave
of glycemic progression, and to access the time dependency of reversibility of prediabetes.
The study tests 4 hypotheses: 1) Among offspring of parents with type 2 diabetes, early
progression from normal to impaired glucose regulation (within 5 yr) occurs in the
highest-risk subjects independently of race, whereas late progression (5-10 yr) displays
racial disparities, and is predicted by physiological, biochemical and behavioral markers; 2)
Early microvascular complications, peripheral vascular disease (PVD), and endothelial
dysfunction manifest during transition from normal to impaired glucose regulation, display
racial disparities, and are predicted by glycemic and nonglycemic factors; 3) The
"metabolically healthy" insulin-sensitive obese (ISO) phenotype displays racial disparities
in its association with cardiometabolic risk factors and incident dysglycemia among
African-Americans and Caucasians offspring of parents with type 2 diabetes; and 4) Duration
of the prediabetic state is a major determinant of, and is inversely related to, the efficacy
of lifestyle intervention to induce regression of the prediabetic phenotype and restoration
of normal glucose regulation. Participants with prediabetes and others who develop
prediabetes during PROP-ABC will receive Intensive Lifestyle intervention (ILI).
We define duration of prediabetes as the interval from date of confirmed prediabetes to the
date of initiation of ILI, stratified to 3 prediabetes intervals: a) <1 yr, b) 1 to <3 yr, c)
3-6 yr. The primary outcome measure is restoration of normal glucose regulation (fasting
plasma glucose <100 mg/dl and 2-hour post-load plasma glucose < 140 mg/dl). Secondary
endpoints include normalization of either fasting plasma glucose or 2-hour post-load plasma
glucose , occurrence of diabetes, insulin sensitivity and secretion. Data will be analyzed
according to the "intention to treat" principle. Based on power calculations, a sample size
of 150 subjects (50/prediabetes interval) would allow detection of medium to large effect off
ILI with ~85% power. Kaplan-Meier survival curves will be generated for the 3 prediabetes
intervals, and log-rank test will be used to analyze the time to occurrence of primary
outcome. The prospective PROP-ABC, designed to identify new cases of prediabetes as they
occur, is uniquely placed to test the time dependency of reversibility of incident
prediabetes.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |